© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 27, 2022
RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.
December 15, 2021
Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.
December 08, 2021
In a recent clinical trial, Evusheld recipients at increased risk of severe COVID-19 infection saw a 77% reduced risk of developing COVID-19.
October 14, 2021
C difficile was found on 45% of shoe soles and 26.2% of private residences.
Acute Myocardial Infarction Peaks Late Night, Early Morning in Patients with OSA
Latest Monkeypox Trends, Vaccines and Public Health Policy by CDC, WHO
Environmental Factors Play a Role in Psychotic Experiences for Adolescent Twins